CD14 and hepatocellular carcinoma: HCC patients who got clinical benefits from ICI treatment exhibited higher percentages of CD4 effector memory T cells, CD8 effector memory T cells, PD-1+ CD8 T cells, HLA-DR+ dendritic cells (DCs), lower amounts of CD14+ MDSCs, CD14+CD16– and CD14+CD16+ monocytes than whoever did not get clinical benefit from ICI treatment (23, 24).